



# Epidemiology Bureau

## WEEKLY DISEASE SURVEILLANCE REPORT

January 1 – April 29, 2017



Notifiable Diseases	January 1 to April 29 (Morbidity Week 1-17)				
	2017			2016	% Difference
	Cases	Deaths	CFR (%)	Cases	*2017 vs 2016
<b>VECTOR-BORNE DISEASES</b>					
Chikungunya	342	1	0.29	685	-50.1
Suspect Dengue	23,526	129	0.55	36,906	-36.3
Probable Dengue	8,544	53	0.62	10,915	-21.7
Confirmed Dengue	58	1	1.72	260	-77.7
Japanese Encephalitis	39	0	0.00	104	-62.5
Malaria	444	0	0.00	1,626	-72.7
<b>FOOD/WATER-BORNE DISEASES</b>					
Acute Bloody Diarrhea	5,145	27	0.52	5,021	2.5
Confirmed Cholera	13	0	0.00	18	-27.8
Confirmed Rotavirus	710	0	0.00	624	13.8
Hepatitis A	148	0	0.00	299	-50.5
Paralytic Shellfish Poisoning	6	0	0.00	16	-62.5
Typhoid	5,905	7	0.12	9,762	-39.5
<b>ZOONOTIC DISEASES</b>					
Anthrax	54	0	0.00	0	5400.0
Leptospirosis	463	45	9.72	252	83.7
Rabies	78	78	100.00	84	-7.1
<b>VACCINE PREVENTABLE DISEASES</b>					
Diphtheria	18	3	16.67	18	0.0
Measles	13	0	0.00	67	-80.6
Neonatal Tetanus	22	17	77.27	33	-33.3
Pertussis	9	0	0.00	16	-43.8
Rubella	191	0	0.00	67	185.1
<b>ADVERSE EVENTS FOLLOWING IMMUNIZATION</b>					
	31	2	6.45	82	-62.2
<b>OTHER DISEASES</b>					
Acute Encephalitis Syndrome	183	7	3.83	136	34.6
Acute Hemorrhagic Fever	6	0	-	14	-57.1
Bacterial Meningitis	526	37	7.03	779	-32.5
Hand, Foot and Mouth Disease	613	1	0.16	397	54.4
Influenza	56	0	0.00	117	-52.1
Influenza-like Illness	15,262	7	0.05	43,295	-64.7
Meningococcal Disease	52	27	51.92	66	-21.2
Hepatitis B	1,123	12	1.07	1,159	-3.1
Hepatitis C	25	1	4.00	31	-19.4
Non-Neonatal Tetanus	281	67	23.84	382	-26.4
<b>DISEASE FOR ERADICATION</b>					
Acute Flaccid Paralysis	Viral Isolation Result		2017	2016	% Difference *2017 vs 2016
	Negative for Polio		78	133	-41.4
	Poliovirus Sabin-like		1	3	-66.7
	Non-polio Enterovirus (NPEV)		5	8	-37.5
	No Stool		21	8	162.5
	Pending		26	-	-
	Total		131	152	-13.8

PREPARED BY:

*[Signature]*  
JUNE CANTATA B. CORPUZ, RN  
Coordinator, PIDSR

*[Signature]*  
JEZZA JONAH D. CRUCENA, RN  
Coordinator, VPD

APPROVED BY:

*[Signature]*  
IRMA L. ASUNCION, MD, MHA, CESO IV  
Director IV, Epidemiology Bureau

*[Signature]*  
GENESIS MAY J. SAMONTE, MD, MSc, PHSAE  
OIC, Division Chief PHSD

**Philippine Integrated  
Disease Surveillance and  
Response**  
“Our First Line of Defense”



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.